There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB), Xoma (XOMA) and Co-Diagnostics (CODX) with bullish sentiments.
Biogen (BIIB)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Biogen today and set a price target of $335.00. The company’s shares closed last Monday at $299.39.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 11.4% and a 47.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Biogen with a $306.96 average price target, representing a 5.5% upside. In a report released yesterday, Cowen & Co. also assigned a Buy rating to the stock with a $325.00 price target.
See today’s analyst top recommended stocks >>
Xoma (XOMA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Xoma today and set a price target of $30.00. The company’s shares closed last Monday at $24.31, close to its 52-week high of $26.90.
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.4% and a 38.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xoma with a $27.50 average price target.
Co-Diagnostics (CODX)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Co-Diagnostics, with a price target of $2.00. The company’s shares closed last Monday at $0.99, close to its 52-week low of $0.69.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -15.8% and a 33.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.
Co-Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $2.00, a 100.0% upside from current levels. In a report issued on December 3, Maxim Group also maintained a Buy rating on the stock with a $2.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
